Phase I/II Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of a Single Escalating Dose of PER977 Following Administration of Unfractionated Heparin

Trial Profile

Phase I/II Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of a Single Escalating Dose of PER977 Following Administration of Unfractionated Heparin

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 May 2017

At a glance

  • Drugs Ciraparantag (Primary)
  • Indications Haemorrhage
  • Focus Therapeutic Use
  • Sponsors Perosphere
  • Most Recent Events

    • 23 May 2015 Planned End Date changed from 1 Mar 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
    • 18 Dec 2014 Additional study cohorts 5 and 6 for doses 500 mg and 600 mg are added in treatment table. Planned number of patients also changed from 40 to 60 as reported by ClinicalTrials.gov record.
    • 18 Dec 2014 Planned number of patients changed from 40 to 60 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top